9 Biotechnology Stocks to Sell Now

CVM, EPRS, OHRP, TSRX, VICL, SGYP, VSTM, CLDX, TRVN slump in weekly rankings

For the current week, the overall ratings of nine biotechnology stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, CEL-SCI Corporation (CVM) falls to a D (“sell”), worse than last week’s grade of C (“hold”). CEL-SCI is developing new immune system based treatments for cancer and infectious diseases. In Portfolio Grader’s specific subcategories of Equity and Cash Flow, CVM also gets F’s. For more information, get Portfolio Grader’s complete analysis of CVM stock.

The rating of EPIRUS Biopharmaceuticals, Inc. (EPRS) declines this week from a C to a D. The stock also gets an F in Earnings Revisions. To get an in-depth look at EPRS, get Portfolio Grader’s complete analysis of EPRS stock.

Ohr Pharmaceutical Inc (OHRP) gets weaker ratings this week as last week’s C drops to a D. Ohr Pharmaceutical develops pharmaceuticals for wound care and to treat cachexia. The stock gets F’s in Earnings Revisions and Equity. For more information, get Portfolio Grader’s complete analysis of OHRP stock.

Slipping from a C to a D rating, Trius Therapeutics, Inc. (TSRX) takes a hit this week. Trius Therapeutics is a biopharmaceutical company. The stock receives F’s in Earnings Growth, Earnings Momentum and Equity. Cash Flow and Sales Growth also get F’s. To get an in-depth look at TSRX, get Portfolio Grader’s complete analysis of TSRX stock.

This week, Vical Incorporated (VICL) drops from a C to a D rating. Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of VICL stock.

Synergy Pharmaceuticals, Inc.’s (SGYP) rating falls this week to an F (“strong sell”), down from last week’s D (“sell”). Synergy Pharmaceuticals is a biopharmaceutical company focused on the development of drugs to treat gastrointestinal disorders and diseases. The stock gets F’s in Equity and Cash Flow. As of July 29, 2015, 23.6% of outstanding Synergy Pharmaceuticals, Inc. shares were held short. To get an in-depth look at SGYP, get Portfolio Grader’s complete analysis of SGYP stock.

Verastem, Inc. (VSTM) experiences a ratings drop this week, going from last week’s D to an F. Verastem is a biopharmaceutical company which is focused on discovering and developing novel drugs that selectively target cancer stem cells in breast and other cancers along with proprietary companion diagnostics. The stock gets F’s in Equity and Cash Flow. As of July 29, 2015, 12.5% of outstanding Verastem, Inc. shares were held short. For more information, get Portfolio Grader’s complete analysis of VSTM stock.

This week, Celldex Therapeutics, Inc.’s (CLDX) rating worsens to a D from the company’s C rating a week ago. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The stock also gets an F in Equity. As of July 29, 2015, 16.6% of outstanding Celldex Therapeutics, Inc. shares were held short. To get an in-depth look at CLDX, get Portfolio Grader’s complete analysis of CLDX stock.

Trevena, Inc.’s (TRVN) rating weakens this week, dropping to a D versus last week’s C. The stock gets F’s in Equity and Cash Flow. For more information, get Portfolio Grader’s complete analysis of TRVN stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2015/07/9-biotechnology-stocks-to-sell-now-cvm-eprs-ohrp/.

©2019 InvestorPlace Media, LLC